Natural remedy use in a prospective cohort of breast cancer patients in southern Sweden

References

• Adler SR, Fosket JR. Disclosing complementary and alternative medicine use in the medical encounter: A qualitative study in women with breast cancer. J Fam Pract 1999; 48:453–8.
   PubMed Web of Science ®Google Scholar
• Gerber B, Scholz C, Reimer T, Briese V, Janni W. Complementary and alternative therapeutic approaches in patients with early breast cancer: A systematic review. Breast Cancer Res Treat 2006;95:199–209.
   PubMed Web of Science ®Google Scholar
• Sparreboom A, Cox MC, Acharya MR, Figg WD. Herbal remedies in the United States: Potential adverse interactions with anticancer agents. J Clin Oncol 2004;22:2489–503.
   PubMed Web of Science ®Google Scholar
• Jacobson JS, Workman SB, Kronenberg F. Research on complementary/alternative medicine for patients with breast cancer: A review of the biomedical literature. J Clin Oncol 2000;18:668–83.
   PubMed Web of Science ®Google Scholar
• Greenlee H, Hershman DL, Jacobson JS. Use of antioxidant supplements during breast cancer treatment: A comprehensive review. Breast Cancer Res Treat 2009;115: 437–52.
   PubMed Web of Science ®Google Scholar
• Bardia A, Barton DL, Prokop LJ, Bauer BA, Moynihan TJ. Efficacy of complementary and alternative medicine therapies in relieving cancer pain: A systematic review. J Clin Oncol 2006;24:5457–64.
   PubMedGoogle Scholar
• Burstein HJ, Gelber S, Guadagnoli E, Weeks JC. Use of alternative medicine by women with early-stage breast cancer. N Engl J Med 1999;340:1733–9.
   PubMed Web of Science ®Google Scholar
• DiGianni LM, Kim HT, Emmons K, Gelman R, Kalkbrenner KJ, Garber JE. Complementary medicine use among women enrolled in a genetic testing program. Cancer Epidemiol Biomarkers Prev 2003;12:321–6.
   PubMedGoogle Scholar
• Greenlee H, Kwan ML, Ergas IJ, Sherman KJ, Krathwohl SE, Bonnell C, . Complementary and alternative therapy use before and after breast cancer diagnosis: The Pathways Study. Breast Cancer Res Treat 2009;117:653–65.
   PubMed Web of Science ®Google Scholar
• NCCAM. National Center for Complementary and Alternative Medicine. 2009 [updated 2009 Jan 16; cited 2009 Jan 16]; Available from: http://nccam.nih.gov/health/whatiscam/overview.htm.
   Google Scholar
• Pedersen CG, Christensen S, Jensen AB, Zachariae R. Prevalence, socio-demographic and clinical predictors of post-diagnostic utilisation of different types of complementary and alternative medicine (CAM) in a nationwide cohort of Danish women treated for primary breast cancer. Eur J Cancer 2009;45:3172–81.
   PubMedGoogle Scholar
• Nilsson M, Trehn G, Asplund K. Use of complementary and alternative medicine remedies in Sweden. A population-based longitudinal study within the northern Sweden MONICA Project. Multinational Monitoring of Trends and Determinants of Cardiovascular Disease. J Intern Med 2001;250:225–33.
   PubMed Web of Science ®Google Scholar
• Malekzadeh F, Rose C, Ingvar C, Jernström H. [Natural remedies and hormone preparations—potential risk for breast cancer patients. A study surveys the use of agents which possibly counteract with the treatment]. Lakartidningen 2005;102:3226–8, 30–1.
   PubMedGoogle Scholar
• DiGianni LM, Garber JE, Winer EP. Complementary and alternative medicine use among women with breast cancer. J Clin Oncol 2002;20(Suppl 18): S34–8.
   Google Scholar
• Rakovitch E, Pignol JP, Chartier C, Ezer M, Verma S, Dranitsaris G, . Complementary and alternative medicine use is associated with an increased perception of breast cancer risk and death. Breast Cancer Res Treat 2005;90: 139–48.
   PubMed Web of Science ®Google Scholar
• Nowack R. Review article: Cytochrome P450 enzyme, and transport protein mediated herb-drug interactions in renal transplant patients: Grapefruit juice, St John's Wort - and beyond! Nephrology (Carlton) 2008;13:337–47.
   PubMed Web of Science ®Google Scholar
• Myers CD, Jacobsen PB, Huang Y, Frost MH, Patten CA, Cerhan JR, . Familial and perceived risk of breast cancer in relation to use of complementary medicine. Cancer Epidemiol Biomarkers Prev 2008;17:1527–34.
   PubMedGoogle Scholar
• Boivin J, Schmidt L. Use of complementary and alternative medicines associated with a 30% lower ongoing pregnancy/live birth rate during 12 months of fertility treatment. Hum Reprod 2009;24:1626–31.
   PubMed Web of Science ®Google Scholar
• Bair YA, Gold EB, Zhang G, Rasor N, Utts J, Upchurch DM, . Use of complementary and alternative medicine during the menopause transition: Longitudinal results from the Study of Women's Health Across the Nation. Menopause 2008;15:32–43.
   PubMed Web of Science ®Google Scholar
• Kupferer EM, Dormire SL, Becker H. Complementary and alternative medicine use for vasomotor symptoms among women who have discontinued hormone therapy. J Obstet Gynecol Neonatal Nurs 2009;38:50–9.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Antona C, Ingelman-Sundberg M. Cytochrome P450 pharmacogenetics and cancer. Oncogene 2006;25: 1679–91.
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Brosen K, Dahl ML, Gram LF, Kasper S, Roots I, . CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: A first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001; 104:173–92.
   PubMed Web of Science ®Google Scholar
• Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: Prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 2004;310:1062–75.
   PubMed Web of Science ®Google Scholar
• Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, . Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003;95:1758–64.
   PubMed Web of Science ®Google Scholar
• Menendez JA, Lupu R, Colomer R. Exogenous supplementation with omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA; 22:6n-3) synergistically enhances taxane cytotoxicity and downregulates Her-2/neu (c-erbB-2) oncogene expression in human breast cancer cells. Eur J Cancer Prev 2005;14:263–70.
   PubMed Web of Science ®Google Scholar